Per Soelberg Sørensen

Per Soelberg Sørensen's AcademicInfluence.com Rankings

Medical

#1930

World Rank

#2317

Historical Rank

Neurology

#185

World Rank

#258

Historical Rank

medical Degrees

Per Soelberg Sørensen

Philosophy

#5692

World Rank

#8568

Historical Rank

Logic

#2926

World Rank

#4002

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Per Soelberg Sørensen's Degrees

Doctorate Medicine University of Copenhagen
PhD Neurology University of Copenhagen

Why Is Per Soelberg Sørensen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Per Soelberg Sørensen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2017) (3544)
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (2011) (2511)
Defining the clinical course of multiple sclerosis (2014) (2372)
The relation between inflammation and neurodegeneration in multiple sclerosis brains (2009) (1223)
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis (2013) (1170)
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study (2001) (1072)
The changing demographic pattern of multiple sclerosis epidemiology (2010) (961)
Remyelination is extensive in a subset of multiple sclerosis patients. (2006) (722)
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. (2010) (708)
Multiple Sclerosis Severity Score (2005) (642)
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility (2019) (589)
EFNS guidelines on diagnosis and management of neuromyelitis optica (2010) (414)
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring (2007) (391)
The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review (2015) (370)
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis (2003) (354)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis (2018) (319)
Factors influencing success of clinical genome sequencing across a broad spectrum of disorders (2015) (319)
Widespread Demyelination in the Cerebellar Cortex in Multiple Sclerosis (2007) (312)
Stroke incidence and risk factors for stroke in Copenhagen, Denmark. (1988) (306)
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview (2015) (265)
EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases (2008) (254)
Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. (2000) (253)
Demyelination versus remyelination in progressive multiple sclerosis. (2010) (249)
Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis (1998) (243)
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab (2012) (239)
Evolving concepts in the treatment of relapsing multiple sclerosis (2017) (231)
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis (2018) (224)
Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis (2005) (218)
Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression (2013) (214)
Immunogenicity of interferon‐β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration (2000) (214)
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis (2011) (205)
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis (2014) (203)
Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. (1994) (202)
Metastatic epidural spinal cord compression. Results of treatment and survival (1990) (201)
Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. (1983) (201)
Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS (2009) (200)
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis (2010) (200)
Appearance and disappearance of neutralizing antibodies during interferon-beta therapy (2005) (198)
Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study (2018) (193)
Intracranial pressure and cerebrospinal fluid outflow conductance in healthy subjects. (1991) (190)
Multiple sclerosis after infectious mononucleosis. (2007) (189)
Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial (2004) (177)
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis (2014) (173)
Metastatic spinal cord compression (2005) (172)
Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. (1990) (158)
Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. (2013) (149)
Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. (2004) (145)
Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS (2000) (144)
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a (2003) (135)
FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS (2014) (134)
EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses (2005) (133)
Cell-based therapeutic strategies for multiple sclerosis (2017) (128)
Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19 (2020) (128)
A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis (2015) (127)
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients (2014) (126)
A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis (2015) (126)
Depression in idiopathic Parkinson's disease treated with citalopram: A placebo-controlled trial (1998) (126)
Danish very-low-dose aspirin after carotid endarterectomy trial. (1988) (123)
Intravenous immunoglobulin G for the treatment of relapsing–remitting multiple sclerosis: a meta‐analysis (2002) (120)
Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial (2011) (115)
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study (2011) (114)
The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility (2017) (113)
Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis (2004) (113)
Intracranial pressure, conductance to cerebrospinal fluid outflow, and cerebral blood flow in patients with benign intracranial hypertension (pseudotumor cerebri) (1985) (110)
A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis (2015) (107)
Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. (2000) (107)
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis (2018) (106)
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper (2016) (106)
IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS (2004) (106)
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects (2016) (104)
Cerebrospinal fluid vasopressin in neurological and psychiatric disorders. (1985) (104)
The Six Spot Step Test: a new measurement for walking ability in multiple sclerosis (2006) (104)
A Placebo-Controlled, Double-Blind, Cross-Over Trial of Flunarizine in Common Migraine (1986) (103)
Cerebral blood flow in patients with normal-pressure hydrocephalus before and after shunting. (1987) (102)
Differential microRNA expression in blood in multiple sclerosis (2013) (99)
New management algorithms in multiple sclerosis. (2014) (98)
Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity (2009) (98)
Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop (2018) (98)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (98)
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort (2013) (96)
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial (2009) (95)
Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study (2009) (89)
Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis (2009) (89)
Cerebrospinal fluid flow and production in patients with normal pressure hydrocephalus studied by MRI (1994) (87)
A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis (2002) (86)
Association between an interleukin-13 promoter polymorphism and atopy. (2003) (84)
Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis (2012) (83)
CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis (2013) (83)
Familial effects on the clinical course of multiple sclerosis (2006) (82)
Sexual dysfunction in male and female patients with epilepsy: A study of 86 outpatients (1990) (82)
Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders (2019) (81)
Cognitive impairment in newly diagnosed multiple sclerosis patients: A 4-year follow-up study (2006) (80)
Motor disturbances in normal-pressure hydrocephalus. Special reference to stance and gait. (1986) (79)
Intracerebral haemorrhage after carotid endarterectomy. (1987) (79)
A systematic review of the incidence and prevalence of cancer in multiple sclerosis (2015) (77)
Natalizumab in progressive MS (2014) (77)
Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results (2008) (76)
Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-β treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression (2008) (74)
The Multiple Sclerosis Care Unit (2018) (74)
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. (2019) (73)
Role of B Cells in Multiple Sclerosis and Related Disorders (2020) (73)
Clinical course and prognosis of pseudotumor cerebri. A prospective study of 24 patients (1988) (72)
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci (2010) (72)
Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial (2010) (72)
Flunarizine Versus Metoprolol in Migraine Prophylaxis: A Double‐Blind, Randomized Parallel Group Study of Efficacy and Tolerability (1991) (71)
Prevalence of stroke in a district of Copenhagen (1982) (69)
Why does the north–south gradient of incidence of multiple sclerosis seem to have disappeared on the Northern hemisphere? (2011) (69)
Effect of baclofen on gait in spastic MS patients. (2000) (69)
Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS (2006) (68)
Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis (2011) (68)
Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies (2016) (68)
The diagnostic reliability of magnetically evoked motor potentials in multiple sclerosis (1992) (67)
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. (2006) (66)
Sumatriptan has no clinically relevant effect in the treatment of episodic tension‐type headache (1996) (65)
The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients (2006) (65)
Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1 (2009) (64)
The Genetic Association of Variants in CD6, TNFRSF1A and IRF8 to Multiple Sclerosis: A Multicenter Case-Control Study (2011) (64)
Increased brain water self-diffusion in patients with idiopathic intracranial hypertension. (1995) (62)
Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP (2009) (61)
Comorbidity in Multiple Sclerosis (2020) (61)
Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. (2016) (61)
Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect (2015) (60)
Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. (2006) (60)
Linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis (1999) (59)
CD4+ memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis (2006) (59)
Identification of new sensitive biomarkers for the in vivo response to interferon‐β treatment in multiple sclerosis using DNA‐array evaluation (2009) (58)
A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS (1999) (57)
The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis (2001) (57)
Reproduction and the risk of multiple sclerosis (2013) (56)
Early versus later treatment start in multiple sclerosis: a register‐based cohort study (2018) (56)
Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E) (2002) (54)
Progressive multiple sclerosis, cognitive function, and quality of life (2018) (54)
Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis (2012) (53)
Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab (2011) (52)
Second occurrence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. (1995) (52)
CSF and plasma vasopressin concentrations in dementia. (1983) (51)
Metastatic spinal cord compression secondary to lung cancer. (1992) (51)
Endocrine studies in patients with pseudotumor cerebri. Estrogen levels in blood and cerebrospinal fluid. (1986) (50)
Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality (2017) (50)
Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (2005) (49)
Cerebrospinal fluid vasopressin and increased intracranial pressure (1984) (49)
Visual evoked potentials in pseudotumor cerebri. (1985) (48)
Safety concerns and risk management of multiple sclerosis therapies. (2017) (48)
MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS) (2005) (48)
Resistance to cerebrospinal fluid outflow and intracranial pressure in patients with hydrocephalus after subarachnoid haemorrhage (1987) (48)
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis (2019) (47)
Increased Self-Diffusion of Brain Water in Hydrocephalus Measured MR Imaging (1994) (47)
International consensus statement on the use of disease-modifying agents in multiple sclerosis (2002) (46)
Persistence of neutralizing antibodies after discontinuation of IFNβ therapy in patients with relapsing-remitting multiple sclerosis (2006) (45)
Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. (2007) (45)
Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study (2020) (45)
Initial high-efficacy disease-modifying therapy in multiple sclerosis (2020) (44)
The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review (2015) (44)
Assessment of CSF dynamics and venous flow in the superior sagittal sinus by MRI in idiopathic intracranial hypertension: a preliminary study (1994) (44)
The changing course of multiple sclerosis: rising incidence, change in geographic distribution, disease course, and prognosis (2019) (44)
Disease protection and interleukin‐10 induction by endogenous interferon‐β in multiple sclerosis? (2011) (44)
Multiple sclerosis impairs regional functional connectivity in the cerebellum☆ (2013) (44)
Increased brain water content in pseudotumour cerebri measured by magnetic resonance imaging of brain water self diffusion. (1989) (43)
Pulsed immune reconstitution therapy in multiple sclerosis (2019) (43)
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study (2013) (43)
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod (2017) (43)
Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study (2018) (43)
Expanded functional coupling of subcortical nuclei with the motor resting-state network in multiple sclerosis (2013) (43)
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development (2014) (42)
The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. (2020) (42)
Neutralising antibodies to interferon β in multiple sclerosis (2007) (42)
Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis (2020) (41)
Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark (2016) (41)
Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity (1996) (41)
Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. (2005) (41)
Using measurements of neutralizing antibodies: the challenge of IFN‐β therapy (2007) (39)
Neutralizing antibodies against interferon-Beta. (2008) (39)
Studies of vasopressin in the human cerebrospinal fluid (1986) (39)
CSF‐amine metabolites in depression, dementia and in controls (1987) (39)
Significant variation in mortality and functional outcome after acute ischaemic stroke between western countries: data from the tinzaparin in acute ischaemic stroke trial (TAIST) (2005) (38)
Are ex vivo neutralising antibodies against IFN-β always detrimental to therapeutic efficacy in multiple sclerosis? (2007) (37)
Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study (2018) (37)
Gene expression analysis of interferon-β treatment in multiple sclerosis (2008) (37)
Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis (2006) (37)
High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial (2017) (37)
Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis (2012) (36)
Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey (2006) (36)
Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis (2018) (36)
Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen. (1993) (36)
Minocycline added to subcutaneous interferon β‐1a in multiple sclerosis: randomized RECYCLINE study (2016) (36)
The Danish Multiple Sclerosis Treatment Register (2016) (35)
Cerebrospinal fluid bombesin and calcitonin in patients with central nervous system metastases from small-cell lung cancer. (1986) (35)
Smoking affects the interferon beta treatment response in multiple sclerosis (2018) (35)
Vasopressin in the cerebrospinal fluid of patients with normal pressure hydrocephalus and benign intracranial hypertension. (1982) (35)
Cerebrospinal fluid vasopressin in benign intracranial hypertension (1982) (34)
Defining active progressive multiple sclerosis (2017) (34)
Breakthrough disease during interferon-&bgr; therapy in MS: No signs of impaired biologic response (2010) (34)
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results (2017) (34)
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis (2016) (34)
Non-compliance in community psychiatry: Failed appointments in the referral system to psychiatric outpatient treatment (2002) (34)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (33)
FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4+CD25high T cells in multiple sclerosis (2012) (33)
A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: Preliminary results (1997) (33)
Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis (2010) (33)
Health-related quality of life in secondary progressive multiple sclerosis (2007) (32)
Safety concerns and risk management of multiple sclerosis therapies (2017) (32)
Brain water accumulation in pseudotumour cerebri demonstrated by MR-imaging of brain water self-diffusion. (1990) (32)
Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. (2007) (32)
Correlations of brain MRI parameters to disability in multiple sclerosis (2001) (32)
Essential tremor treated with propranolol: Lack of correlation between clinical effect and plasma propranolol levels (1981) (31)
Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale (2005) (31)
Dynamic T‐lymphocyte Chemokine Receptor Expression Induced by Interferon‐beta Therapy in Multiple Sclerosis (2006) (31)
Erratum: Remyelination is extensive in a subset of multiple sclerosis patients (Brain (2006) 129, PART 12, (3165-3172) DOI: 10.1093/brain/awl217) (2007) (31)
Transient ischaemic attacks in young patients: a thromboembolic or migrainous manifestation? A 10 year follow up study of 46 patients. (1990) (31)
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients (2016) (31)
Resting‐state connectivity of pre‐motor cortex reflects disability in multiple sclerosis (2013) (30)
Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients (2010) (30)
The MIRROR Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and MRI Efficacy of Subcutaneous Ofatumumab in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) (S23.006) (2014) (30)
The role of intravenous immunoglobulin in the treatment of multiple sclerosis (2003) (30)
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. (2007) (30)
Gene expression analysis of relapsing–remitting, primary progressive and secondary progressive multiple sclerosis (2013) (29)
Measurement of Blood Flow in the Superior Sagittal Sinus in Healthy Volunteers, and in Patients with Normal Pressure Hydrocephalus and Idiopathic Intracranial Hypertension with Phase-Contrast Cine MR Imaging (1996) (29)
Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. (2012) (28)
Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis (2013) (28)
Vasopressin in plasma and ventricular cerebrospinal fluid during dehydration, postural changes, and nausea. (1985) (28)
Comparative effectiveness of teriflunomide and dimethyl fumarate (2019) (27)
Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis (2018) (27)
Multiple sclerosis: pathophysiology revisited (2005) (27)
Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs (2004) (27)
Principles of a new treatment algorithm in multiple sclerosis (2011) (27)
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial (2021) (26)
The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis (2009) (26)
Linkage analysis of a candidate region in Scandinavian sib pairs with multiple sclerosis reveals linkage to chromosome 17q (2000) (26)
Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis (2004) (25)
Gender and autoimmune comorbidity in multiple sclerosis (2014) (25)
Multi‐slice echo‐planar spectroscopic MR imaging provides both global and local metabolite measures in multiple sclerosis (2005) (25)
Prediction of antibody persistency from antibody titres to natalizumab (2012) (24)
Health-related quality of life in secondary progressive multiple sclerosis. (2007) (24)
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer (2021) (24)
Fatal neurogenic pulmonary edema in a patient with progressive multiple sclerosis (2008) (24)
IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions (2007) (23)
Association between age at onset of multiple sclerosis and vitamin D level–related factors (2016) (23)
Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine (2016) (23)
Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically (2005) (23)
Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials (2003) (23)
Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis (2016) (23)
Is the treatment effect of IFN-β restored after the disappearance of neutralizing antibodies? (2008) (23)
Correction: Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression (2013) (22)
Biological markers in body fluids for activity and progression in multiple sclerosis. (1999) (22)
Significantly increased fractions of transformed to total alpha2-macroglobulin concentrations in plasma from patients with multiple sclerosis. (2004) (22)
Steady state kinetics of pyridostigmine in myasthenia gravis (1984) (22)
Prediction of response to interferon therapy in multiple sclerosis (2014) (22)
Worsening of disability caused by relapses in multiple sclerosis: A different approach. (2019) (21)
Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships (2017) (21)
Physical and social environment and the risk of multiple sclerosis. (2013) (21)
[Diagnosis of multiple sclerosis: revision of the McDonald criteria]. (2007) (21)
Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon‐β (2009) (21)
Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis (2012) (21)
Endogenous Interferon-β-Inducible Gene Expression and Interferon-β-Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis (2015) (20)
Prevalence of mitral valve prolapse in younger patients with cerebral ischaemic attacks. A blinded controlled study. (2009) (20)
Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients (2003) (20)
Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis (2015) (20)
Cognitive deficits in multiple sclerosis: correlations with T2 changes in normal appearing brain tissue (2012) (20)
Severe headache as the only symptom of long-standing shunt dysfunction in hydrocephalic children with normal or slit ventricles revealed by computed tomography (2004) (19)
The relationship between MRI and PET changes and cognitive disturbances in MS (2006) (19)
Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab (2013) (19)
The window of opportunity for treatment of progressive multiple sclerosis. (2020) (19)
No linkage or association of the nitric oxide synthase genes to multiple sclerosis (2001) (19)
Ophthalmologic prognosis in Benign Intracranial Hypertension (1985) (19)
Secondary Progressive and Relapsing Remitting Multiple Sclerosis Leads to Motor-Related Decreased Anatomical Connectivity (2014) (18)
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis (2008) (18)
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network (2021) (18)
Intravenous Polyclonal Human Immunoglobulins in Multiple Sclerosis (2007) (17)
Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder (2021) (17)
Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China (2019) (17)
Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis (2015) (17)
Treatment of multiple sclerosis with IVIg: potential effects and methodology of clinical trials. (1994) (16)
Neurofilament in CSF—A biomarker of disease activity and long-term prognosis in multiple sclerosis (2016) (16)
Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort. (2016) (16)
Expert opinion on the use of cladribine tablets in clinical practice (2020) (16)
Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy (2018) (16)
The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. (2008) (16)
Endogenous and Recombinant Type I Interferons and Disease Activity in Multiple Sclerosis (2012) (15)
Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis (2011) (15)
Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans (2012) (15)
Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. (2017) (15)
Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension (2005) (15)
Cerebrospinal fluid vasopressin as a marker of central nervous system metastases from small-cell bronchogenic carcinoma. (1985) (15)
Correlation between anti‐interferon‐β binding and neutralizing antibodies in interferon‐β‐treated multiple sclerosis patients (2012) (15)
The SH2D2A gene and susceptibility to multiple sclerosis (2008) (14)
Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta. (2016) (14)
Employment, disability pension and income for children with parental multiple sclerosis (2017) (14)
Effects of long-term carbamazepine treatment on water metabolism and plasma vasopressin concentration (2004) (14)
Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis (2009) (14)
Vasopressin release during electroconvulsive therapy (1982) (13)
Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: an exploratory study (2012) (13)
CD26+CD4+T cell counts and attack risk in interferon-treated multiple sclerosis (2005) (13)
Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study (2016) (13)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2020) (13)
Early safety and efficacy of fingolimod treatment in Denmark (2017) (13)
Illegal cannabis use is common among Danes with multiple sclerosis. (2019) (13)
Intravenous polyclonal human immunoglobulins in multiple sclerosis. (2008) (13)
Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis (2019) (12)
European Journal of Neurology: Four years on (1997) (12)
Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study (2019) (12)
Neutralizing antibodies against interferon-β do not predispose antibodies against natalizumab (2011) (12)
Gender effects on treatment response to interferon‐beta in multiple sclerosis (2014) (12)
Tolfenamic acid versus propranolol in the prophylactic treatment of migraine (1994) (12)
A case of malignant lymphoma and myasthenia gravis. (2009) (12)
Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (11)
Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review (2020) (11)
Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents (2017) (11)
Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study. (2020) (11)
Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. (2008) (11)
Comparison of myelography combined with postmyelographic spinal CT and MRI in suspected metastatic disease of the spinal canal (1992) (11)
24-hour cerebrospinal fluid levels of vasopressin in hydrocephalic patients (1985) (10)
Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis (1996) (10)
Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis (2012) (10)
Ozanimod: a better or just another S1P receptor modulator? (2016) (10)
Diagnostic Value of Spinal Computer Tomography in Patients with Intraspinal Metastases Causing Complete Block on Myelography (1991) (9)
[Diagnosis of multiple sclerosis--the 2010 revision of the McDonald criteria]. (2012) (9)
Review: Neutralizing antibodies against interferon-beta (2008) (9)
Prognostic value of in vitro measurements of platelet aggregability and fibrinolytic activity in patients with reversible cerebral ischemic attacks. (1983) (9)
Spinal cord atrophy in anterior‐posterior direction reflects impairment in multiple sclerosis (2017) (9)
Cortical N-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis (2014) (9)
Radiologic features compared to clinical findings in a prospective study of 153 patients with metastatic spinal cord compression treated by radiotherapy (2007) (9)
The association of selected multiple sclerosis symptoms with disability and quality of life: a large Danish self-report survey (2021) (9)
Management of patients with neutralizing antibodies against interferon‐beta: stop IFN‐beta therapy or wait for the antibodies to go away? (2009) (9)
A randomized study of two interferon- beta treatments in relapsing–remitting multiple sclerosis (2006) (9)
[Reduced metabolism in cerebral cortex correlates with MRI changes and cognitive dysfunction in patients with disseminated sclerosis]. (2001) (8)
Oral fumarate for relapsing-remitting multiple sclerosis (2008) (8)
Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655 (2011) (8)
Measurement of Conductance to Cerebrospinal Fluid Outflow by the Steady-State Perfusion Method in Patients with Normal or Increased Intracranial Pressure (1986) (8)
Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis (2021) (8)
Therapeutic interference with leukocyte recirculation in multiple sclerosis (2015) (8)
Acute Relapses of Multiple Sclerosis (2010) (8)
Reduced immunogenicity with a new formulation of interferon-beta-1a (Rebif (R)): 24-week results of a phase IIIb study (2006) (8)
Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network (2021) (8)
Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis (2014) (7)
Do concentrations of neurotransmitters measured in lumbar cerebrospinal fluid reflect the concentrations at brain level? (2005) (7)
Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - NO. (2016) (7)
Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (7)
Multiple sclerosis: Generic glatiramer acetate — a step toward cheaper MS drugs? (2016) (7)
Results from the CLARITY Study: a Phase III, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Oral Cladribine in Relapsing-Remitting Multiple Sclerosis (RRMS) (2009) (7)
Predictors of treatment outcome in patients with paediatric onset multiple sclerosis (2020) (7)
Intravenous immunoglobulin in multiple sclerosis (2007) (7)
Clinical Efficacy of Laquinimod for the Treatment of Multiple Sclerosis; Pooled Analyses from the ALLEGRO and BRAVO Phase III Trials (S01.007) (2012) (7)
Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis (2015) (7)
Pooled Analyses from the ALLEGRO and BRAVO Trials on the Safety and Tolerability of Laquinimod as a Multiple Sclerosis Treatment (P04.132) (2012) (7)
Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study. (2012) (6)
Effects of fingolimod in relapsing-remitting multiple sclerosis (2014) (6)
Antibodies to IFN-beta (2003) (6)
Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study (2021) (6)
Cerebrospinal fluid and plasma vasopressin during short-time induced intracranial hypertension (2005) (6)
Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - NO. (2016) (6)
The chemokine receptor CCR5 Δ32 allele in natalizumab‐treated multiple sclerosis (2014) (6)
Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study). (2013) (6)
Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis (2013) (6)
Expression of melanoma cell adhesion molecule-1 (MCAM-1) in natalizumab-treated multiple sclerosis (2019) (6)
Effects of neutralizing antibodies to interferon beta in multiple sclerosis: a logical paradox (2012) (6)
Flunarizine in Common Migraine Prophylaxis. A Doubl E-Blind, Cross-Over Study (1985) (6)
Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis (2020) (5)
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice (2021) (5)
Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis (2022) (5)
Cladribine in the treatment of multiple sclerosis (2011) (5)
Resistance to cerebrospinal fluid outflow and intracranial pressure in patients with hydrocephales after subarachnoid haemorrhage (2005) (5)
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. (2021) (5)
Disability in progressive MS is associated with T2 lesion changes. (2018) (5)
Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis. (2016) (5)
The gap between effect of drugs and effectiveness of treatments (2007) (5)
Initial High-Efficacy Disease-Modifying Therapy in Multiple Sclerosis (2022) (5)
Linkage analysis suggests a region of importance for multiple sclerosis in 3p14–13 (2001) (5)
[Magnetic resonance imaging compared to myelography and CT. Diagnostic value in patients with suspected medullary spinal compression syndrome]. (1994) (5)
Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (5)
Prophylactic Effect of Flunarizine versus Metoprolol in Migraine (1989) (5)
Neutralising antibodies to interferon-β–measurement, clinical relevance, and management (2006) (4)
Intravenous immunoglobulin treatment in neurologic disorders: yes. (1999) (4)
Periventricular Lucency (Edema) in Computed Tomography and Conductance to CSF Outflow in Patients with High Pressure Hydrocephalus and Normal Pressure Hydrocephalus (1983) (4)
Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2007) (4)
Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis (2009) (4)
The CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY): design of a Phase III trial of oral cladribine in relapsing multiple sclerosis (2007) (4)
Reductions in MRI activity in relapsing-remitting multiple sclerosis achieved with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study (2009) (4)
Natalizumab treatment of progressive multiple sclerosis reduces inflammation and tissue damage - results of a phase 2A proof-of-concept study (2012) (4)
Central motor conduction as a measure of disease progression in early multiple sclerosis (1995) (4)
International consensus statement on the use of disease-modifying agents in multiple sclerosis (2002) (4)
Anatomical Connectivity Mapping – Measuring connectivity changes in Multiple Sclerosis (2012) (4)
Resource allocation to brain research in Europe (2007) (3)
Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS. (2021) (3)
Outflow of cerebrospinal fluid : proceedings of the Alfred Benzon Symposium 27, held at the premises of the Royal Danish Academy of Sciences and Letters, Copenhagen, 5-9 June 1988 (1989) (3)
Disease-free status achieved with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis (2009) (3)
Biopsychosocial Response to the COVID-19 Lockdown in People with Major Depressive Disorder and Multiple Sclerosis (2022) (3)
NAverting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project. (2021) (3)
Breakthrough disease during interferon-β therapy in MS (2010) (3)
REGARD: what can we learn from randomised, open-label, head-to-head studies? (2008) (3)
Analysis of Clinical and Radiological Disease Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets, in the Double-Blind, 96-Week CLARITY Study (2010) (3)
Segmenting Multiple Sclerosis Lesions Using a Spatially Constrained K-Nearest Neighbour Approach (2012) (3)
A follow-up study of Nordic multiple sclerosis candidate gene regions (2007) (3)
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021 (2022) (3)
Carotid artery disease and low cerebral perfusion pressure: symptomatology, operative risk and outcome. (1990) (3)
Highly effective disease-modifying treatment as initial MS therapy (2021) (3)
The gut microbiota in multiple sclerosis varies with disease activity (2023) (3)
Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis. (2019) (3)
Immunogenicity of Rebif (R) New Formulation (interferon beta-1a) in patients with relapsing multiple sclerosis: results from a phase IIIb study (2008) (3)
The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges (2020) (3)
Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. (2007) (2)
Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis: A Danish nationwide study. (2022) (2)
Early-stage multiple sclerosis : what are the treatment options? (2004) (2)
The Effect on MRI of Gammaglobulin Treatment in Relapsing Multiple Sclerosis (2000) (2)
Monthly cycles of methylperdnisolone in combination with interferon beta-1a IM are efficacious in the treatment of early relapsing-remitting multiple sclerosis. The MECOMBIN study. (2009) (2)
Deaths and disability from natalizumab are no longer tolerable: No – (they can be avoided) (2012) (2)
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network (2022) (2)
Reporting clinical trials: full access to all the data. (2002) (2)
Intracerebroventricular infusion but not bolus injection of vasopressin increases the cerebrospinal fluid pressure in awake rabbits. (1990) (2)
Efficacy of cladribine tablets for relapsing-remitting multiple sclerosis in patients with high disease activity: results from the phase III, 96-week CLARITY study (2011) (2)
Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19 (Preprint) (2020) (2)
[Biological treatment of multiple sclerosis]. (2008) (2)
Can we spot the IFNβ nonresponders? (2008) (2)
Cardiac disease in patients with reversible cerebral ischemic events. (2009) (2)
Relapses add to permanent disability in relapsing multiple sclerosis patients. (2021) (2)
Comparison of clinical neurological function and CT response during chemotherapy for initial brain metastases from small cell lung cancer (1994) (2)
Effect of Cerebroventricular Infusion of Vasopressin on Intracranial Pressure, Blood Pressure and Plasma Vasopressin (1986) (2)
Tolerability Profile of Cladribine Tablets Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: Factors Contributing to Treatment Completion in the Double-Blind, 96-Week, Placebo-Controlled CLARITY Study (2011) (2)
Plasma vasopressin, cortisol, and growth hormone concentrations in relation to surgery in the suprasellar region. (2009) (2)
Brain Edema, ICP and CSF Outflow Resistance in Experimental Pneumococcal Meningitis: Effect of Mannitol and Antiinflammatory Drugs (1989) (2)
Use of Anti‐Interferon Beta Antibody Measurements in Multiple Sclerosis (2010) (2)
Interferon-beta-1a: therapeutic effects, tolerability, current and future status in multiple sclerosis (2011) (2)
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets (2022) (2)
Cladribine tablets in patients who had failed prior treatment with injectable disease-modifying drugs for relapsing-remitting multiple sclerosis: evaluation of treatment effect in the CLARITY study (2011) (1)
Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis (2022) (1)
[Metastatic spinal compression syndrome. Symptoms, diagnosis, treatment and prognosis]. (1990) (1)
Tract-oriented statistical group comparison of diffusion in sheet-like white matter (2013) (1)
Nordic trial of methylprednisolone as add-on therapy to interferon-beta for the treatment of relapsing-remitting multiple sclerosis (2008) (1)
A controlled trial of plasma exchange in multiple sclerosis using serial MRI and multimodal evoked potentials as efficacy parameters (1995) (1)
Multiple Sclerosis Management – A Changing Landscape 2013 (2013) (1)
Rethinking MS in Europe: Prioritizing integrated services for people with multiple sclerosis (2020) (1)
Gene expression in smoking and non-smoking patients with multiple sclerosis (2014) (1)
Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis (2021) (1)
Vasopressin Concentration in Cerebrospinal Fluid and Conductance to CSF Outflow in Benign Intracranial Hypertension and Normal Pressure Hydrocephalus (1983) (1)
Calcium Entry Blockers in Migraine Prophylaxis — A Critical Review of Therapeutic Trials (1989) (1)
Rethinking MS in Europe Prioritising Timely Integrated Services for People with Multiple Sclerosis (2020) (1)
Long-Term Prolonged-Release Fampridine Treatment and Health-Related Quality of Life Outcomes: Interim Results of the Enable Study (2013) (1)
Change in Quality of Life Outcomes with Prolonged-Release Fampridine Treatment: Interim Analysis of the ENABLE Study (P03.218) (2013) (1)
039 Rates of lymphopenia in years 1–4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets (2018) (1)
A new millennium? Perhaps. A new European Journal of Neurology? Certainly! (2000) (1)
OR.64. Increased Concentrations of the B Cell Chemokine CXCL13 and Increased Expression of the Th17 Transcription Factor RORC in Multiple Sclerosis (2008) (1)
[Metastatic spinal cord compression in patients with lung cancer]. (1996) (1)
Reconstitution of circulating lymphocyte subsets after treatment with cladribine tablets in the 96-week CLARITY study in relapsing-remitting multiple sclerosis (2010) (1)
Safety and tolerability of Rebif((R)) New Formulation (interferon beta-1a) in patients with relapsing multiple sclerosis: results from a phase IIIb study (2008) (1)
Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-β. (2019) (1)
Neutralising antibodies against interferon beta in multiple sclerosis (2004) (1)
Evaluation of the Treatment Effect of Cladribine Tablets in the Cohort of Patients Who Had Failed Prior Treatment with Injectable Disease-Modifying Drugs: The CLARITY Relapsing-Remitting Multiple Sclerosis Study (2011) (1)
The utility of wearable devices in assessing ambulatory impairments of people with multiple sclerosis in free-living conditions (2021) (1)
Consistent efficacy of cladribine tablets across multiple sclerosis and patient characteristics, in the double-blind, 96-week CLARITY study (2010) (1)
IIIb study in patients with relapsing multiple sclerosis : 96-week results-1 a ( Rebif ® New Formulation ) in a Phase β Safety and immunogenicity of a new formulation of interferon (2009) (1)
[Limited effect of interferon-beta for the treatment of secondary progressive multiple sclerosis]. (2013) (1)
Exploring correlations between changes in lymphocyte counts and clinical/magnetic resonance imaging outcomes in cladribine-treated patients with relapsing-remitting multiple sclerosis: analyses from the double-blind, 96-week CLARITY study (2011) (1)
F.73. Expression Profiling of Blood Mononuclear Cells from Patients with Multiple Sclerosis Identifies Differentially Expressed miRNAs and Their mRNA Targets (2009) (1)
891P Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial (2022) (1)
How effective is natalizumab as second‐line treatment for multiple sclerosis in daily clinical praxis? (2009) (1)
Mitral valve prolapse and cerebral ischemic events: A blinded controlled study (1984) (1)
Increased CSF vasopressin concentration in patients with raised intracranial pressure (1984) (0)
Safety of Using Disease-Modifying Therapy Post-Alemtuzumab Treatment in Patients with Active Relapsing-Remitting Multiple Sclerosis in the Alemtuzumab Clinical Development Program (P6.185) (2016) (0)
Rethinking MS in Europe: Prioritising Timely, Integrated Care for People with Multiple Sclerosis (2020) (0)
progressive multiple sclerosis subcutaneous interferon beta-1a in secondary controlled, phase III study of weekly, low dose, Multicentre, randomised, double blind, placebo (2005) (0)
Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis (2019) (0)
Oral session 3 — Cerebrovascular disorders (1) (2005) (0)
European contribution to MS treatment algorithms: benefits and risk stratification (2015) (0)
Review of the Results of Previous Phase II, Magnetic Resonance Imaging-monitored Clinical Trials (1999) (0)
Expert Opinion on the Use of Cladribine Tablets in Clinical Practice for the Treatment of Relapsing Multiple Sclerosis (2020) (0)
Autonomic response to walk tests is useful for assessing outcome measures in people with multiple sclerosis (2023) (0)
[Multiple sclerosis--the significance of genes. The Danish Society of Neurology]. (2008) (0)
T.69. T Cell Activation and Th2-related Gene Expression Correlate with Disease Activity in Glatiramer Acetate-treated Multiple Sclerosis (2009) (0)
F.27. Gene Expression Analysis of Inteferon-beta and Glatiramer Acetate in Multiple Sclerosis (2008) (0)
Effect of initial high-efficacy disease modifying therapy in relapsing-remitting multiple sclerosis: a nationwide cohort study (2019) (0)
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary. (2022) (0)
Early-Stage Multiple Sclerosis (2012) (0)
Safety of long-term monthly cycles of methylprednisolone in combination with interferon beta- 1a IM in treatment -naive early relapsing-remitting multiple sclerosis patients in the MECOMBIN trial. (2009) (0)
PO10-TU-27 Methylprednisolone as add-on to Interferon-b-1a in treatment naive relapsing-remitting multiple sclerosis (RRMS) patients reduces the annualized relapse rate (2009) (0)
Oral session 2 — Multiple sclerosis (2) (2005) (0)
Therapy-induced antibodies against interferon-β-1a and interferon-β-1b in patients with multiple sclerosis (2001) (0)
Sa.42. Increased Expression of Interleukin-10, Tumor Necrosis Factor and Interleukin-23 in Multiple Sclerosis Patients Treated with Interferon-β (2006) (0)
Long-Term Follow-Up of Laquinimod 0.6 mg in Patients with Relapsing-Remitting Multiple Sclerosis 2 (P3.087) (2016) (0)
of neutralizing antibodies in multiple sclerosis patients Polymorphisms of innate pattern recognition receptors , response to interferon-beta and development (2010) (0)
Sexual Dysfunction in Epileptic Patients: A Preliminary Report (1988) (0)
Oral Cladribine and Fingolimod for Relapsing Multiple Sclerosis REPLY (2010) (0)
[Fampridine and multiple sclerosis]. (2014) (0)
The SH2D2A Gene - Contributions to Our Future Understanding of Multiple Sclerosis (2009) (0)
447: Remyelination is extensive in a subset of multiple sclerosis patients (2008) (0)
We believe that the negative results of PRIVIG are indicative of an absence of benefit. Frequent MRI (2009) (0)
Multiple Sclerosis Therapeutics: Neutralizing antibodies directed against biologic agents to treat multiple sclerosis (2011) (0)
Hazards of cerebrovascular, cardiovascular and lung comorbidities in multiple sclerosis: a nationwide study in Denmark using multiple data (2015) (0)
Childbirth but not cohabiting with children influences the risk of multiple sclerosis (2013) (0)
Natalizumab treatment of multiple sclerosis - a Danish nationwide study with 13 years of follow-up. (2023) (0)
T.71. Effects of Interferon-beta Treatment on T Cell Signature Cytokines and Transcription Factors in Multiple Sclerosis (2009) (0)
Anti-proliferative effects of interferon beta associated with increased expression of p21 (2007) (0)
Multiple Sclerosis Therapeutics: Intravenous immunoglobulin to treat multiple sclerosis (2011) (0)
Dementia: finding the signals in the noise (2005) (0)
A Danish nationwide pharmacoepidemiological study of treatment with teriflumonide (2019) (0)
European contribution to MS treatment algorithms: benefits and risk stratification (2015) (0)
[Magnetic resonance imaging in the diagnosis and follow-up of multiple sclerosis]. (2008) (0)
MESEMS: a randomized, double blind placebo-controlled cross-over study to evaluate safety and efficacy of intravenous administration of autologous mesenchymal stem cells in patients with multiple sclerosis (2015) (0)
Disease-modifying therapy of paediatric onset multiple sclerosis. A nationwide Danish cohort study (2018) (0)
Subject Index Vol. 22, 1983 (1983) (0)
Effect of high-dose Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multiple sclerosis: a randomised, placebo-controlled, phase 2 trial (2014) (0)
CSFandplasma vasopressmconcentrations in dementia (1983) (0)
Editorial (2002) (0)
Editorial: Challenges in the diagnosis and treatment of multiple sclerosis. (2021) (0)
Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis (2012) (0)
Tolerability profile of cladribine tablets therapy for patients with relapsing-remitting multiple sclerosis: factors contributing to treatment completion overall and in patients with high disease activity in the 96-week CLARITY study (2011) (0)
Symptomatic and Complementary Treatments (2016) (0)
Commentary on ‘treating complex personality disorder’: What is a complex personality disorder and how do we treat them? (2012) (0)
Prion‐related diseases and Creutzfeldt–Jakob disease (subacute spongiform encephalopathy) (1996) (0)
Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials MUL T IPLE SCLEROSIS AND RARE P A T HOLOGIES (2003) (0)
Disease progression in early multiple sclerosis monitored by means of magnetically evoked motor potentials, evoked potentials, and magnetic resonance imaging (1993) (0)
62MO Naxitamab pivotal clinical trial planned interim analysis of PFS and OS in patients with relapsed or refractory high-risk neuroblastoma (2022) (0)
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (2018) (0)
109P Impact of anti-drug antibody (ADA) on naxitamab efficacy and safety (2022) (0)
Delayed visual evoked response in benign intracranial hypertension (1984) (0)
[Treatment of multiple sclerosis--now and in future. The Danish Multiple Sclerosis Society and the Danish Multiple Sclerosis Group]. (2007) (0)
Guidance concerning compensation for new therapies in multiple sclerosis patients (1997) (0)
F.61. Antigen-presenting Cell and T Cell Activation in Patients with Relapsing Remitting Multiple Sclerosis Studied by Flow Cytometry and RT-PCR (2009) (0)
Cortical N-Acetyl Aspartate Predicts Long-Term Clinical Disability in Multiple Sclerosis – a Longitudinal MR Spectroscopic Imaging Study (2010) (0)
[Can symptoms in cerebrovascular attacks in patients with internal carotid artery stenosis predict the extent to which cerebral circulation is compromised?]. (1988) (0)
Regional Cerebral Blood Flow in Acute Stroke: Comparison of Two Calcium Antagonists (1994) (0)
[Multiple sclerosis--better prognosis]. (1995) (0)
7th European Charcot Foundation Lecture The role of intravenous immunoglobulin in the treatment of multiple sclerosis (2003) (0)
Visual Evoked Potentials in Patients with Hydrocephalus or Intracranial Hypertension (1986) (0)
Contents, Vol. 22, 1983 (1983) (0)
Erratum: Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (Cell (2019) 178(1) (262), (S0092867419306798), (10.1016/j.cell.2019.06.016)) (2020) (0)
A Cross-sectional Study of 21 Newly Diagnosed Relapse-Remitting Multiple Sclerosis Patients with PET, MRI and Tests of Cognitive Function (2002) (0)
Reply (1982) (0)
Disease-modifying treatments for relapsing–remitting multiple sclerosis (2013) (0)
Identification of microRNA changes in the third trimester of pregnancy compared to the post-partum period in multiple sclerosis patients (2014) (0)
Correlations of cerebral glucose metabolism with cognitive impairment in multiple sclerosis (1996) (0)
[Treatment of disseminated sclerosis with beta-inferferon--why and why not?]. (1999) (0)
BENIGN INTRACRANIAL HYPERTENSION (1976) (0)
Multi-slice echo-planar spectroscopy for regional metabolic analysis in MS (2004) (0)
Offspring of Parents with Multiple Sclerosis Achieve Higher Grades and Choose Health-Related Educations (P1.382) (2016) (0)
[Multiple Sclerosis Treatment Registry]. (2012) (0)
Safety and immunogenicity of interferon beta-1a (Rebif (R) New Formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 48-week results (2007) (0)
Oral Sessions (2014) (0)
Assessment of Theory of Mind and emotions in multiple sclerosis (2008) (0)
Reply to Freedman and Burks (2007) (0)
Chapter 30. Acute Relapses of Multiple Sclerosis (2008) (0)
[Preventive drug therapy of transient cerebral ischemic attacks]. (1982) (0)
Multi-slice echo planar spectroscopic imaging in multiple sclerosis (2003) (0)
Design for the Next Trials of Neurodegeneration (2007) (0)
[Multiple epidural metastases and development of secondary metastatic spinal cord compression]. (1998) (0)
[Diagnosis and treatment of metastatic spinal compression syndrome]. (1990) (0)
Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis (2022) (0)

This paper list is powered by the following services:

Other Resources About Per Soelberg Sørensen

www.ms-research.dk

What Schools Are Affiliated With Per Soelberg Sørensen?

Per Soelberg Sørensen is affiliated with the following schools:

University of Copenhagen

Per Soelberg Sørensen's Academic­Influence.com Rankings

Per Soelberg Sørensen's Degrees

Why Is Per Soelberg Sørensen Influential?

Per Soelberg Sørensen's Published Works

Published Works

Other Resources About Per Soelberg Sørensen

What Schools Are Affiliated With Per Soelberg Sørensen?

Per Soelberg Sørensen's AcademicInfluence.com Rankings